scholarly article | Q13442814 |
P50 | author | Gunter Schneider | Q1554915 |
James Henderson Naismith | Q17507299 | ||
Robert Schnell | Q84817083 | ||
Ylva Lindqvist | Q28324830 | ||
David W. Gray | Q55175940 | ||
Lucile Moynié | Q60678342 | ||
P2093 | author name string | Mahavir Singh | |
Ayssar A Elamin | |||
Anthony G Hope | |||
Holger Kneuper | |||
Susanne Schach | |||
Cyprian D Cukier | |||
P2860 | cites work | Pseudomonas Genome Database: improved comparative analysis and population genomics capability for Pseudomonas genomes | Q24609340 |
Medium- and short-chain dehydrogenase/reductase gene and protein families : the SDR superfamily: functional and structural diversity within a family of metabolic and regulatory enzymes | Q24642281 | ||
Structure-based virtual screening for drug discovery: a problem-centric review | Q27022502 | ||
Structure of beta-ketoacyl-[acyl carrier protein] reductase from Escherichia coli: negative cooperativity and its structural basis | Q27635477 | ||
Crystal structure of MabA from Mycobacterium tuberculosis, a reductase involved in long-chain fatty acid biosynthesis | Q27639230 | ||
Crystal structure of a 3-oxoacyl-(acylcarrier protein) reductase (BA3989) from Bacillus anthracis at 2.4-A resolution | Q27648489 | ||
Structure of 3-ketoacyl-(acyl-carrier-protein) reductase from Rickettsia prowazekii at 2.25 Å resolution | Q27673602 | ||
The AEROPATH project targetingPseudomonas aeruginosa: crystallographic studies for assessment of potential targets in early-stage drug discovery | Q27675787 | ||
Crystal structure and fluorescence studies reveal the role of helical dimeric interface of staphylococcal FabG1 in positive cooperativity for NADPH | Q27676871 | ||
Crystal structure of hexanoyl-CoA bound to β-ketoacyl reductase FabG4 of Mycobacterium tuberculosis | Q27683485 | ||
Structural insights into the mechanism and inhibition of the β-hydroxydecanoyl-acyl carrier protein dehydratase from Pseudomonas aeruginosa | Q27683498 | ||
Pseudomonas aeruginosa: all roads lead to resistance | Q28240246 | ||
Integration-proficient plasmids for Pseudomonas aeruginosa: site-specific integration and use for engineering of reporter and expression strains | Q73301855 | ||
Finding the sweet spot: the role of nature and nurture in medicinal chemistry | Q84032484 | ||
Prediction and analysis of the protein interactome in Pseudomonas aeruginosa to enable network-based drug target selection | Q28481505 | ||
Isolation and characterization of beta-ketoacyl-acyl carrier protein reductase (fabG) mutants of Escherichia coli and Salmonella enterica serovar Typhimurium | Q28563574 | ||
A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants | Q29547327 | ||
Ligand efficiency: a useful metric for lead selection | Q29617403 | ||
NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors | Q30887851 | ||
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids | Q33244527 | ||
Lessons learnt from assembling screening libraries for drug discovery for neglected diseases | Q33309109 | ||
Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery | Q34090225 | ||
The antibacterial efficacy of an aceraceous plant [Shantung maple (Acer truncatum Bunge)] may be related to inhibition of bacterial beta-oxoacyl-acyl carrier protein reductase (FabG). | Q34587342 | ||
Forty years of bacterial fatty acid synthesis | Q34610848 | ||
Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes | Q34766191 | ||
Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery? | Q35350186 | ||
Fatty acid biosynthesis as a target for novel antibacterials | Q35713880 | ||
Functional complementation of the essential gene fabG1 of Mycobacterium tuberculosis by Mycobacterium smegmatis fabG but not Escherichia coli fabG | Q35879195 | ||
The reductase steps of the type II fatty acid synthase as antimicrobial targets | Q36052456 | ||
Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. | Q36724203 | ||
Fatty acid synthesis in protozoan parasites: unusual pathways and novel drug targets. | Q37160877 | ||
In vitro precursor-directed synthesis of polyketide analogues with coenzyme a regeneration for the development of antiangiogenic agents | Q37350442 | ||
Pseudomonas aeruginosa - a phenomenon of bacterial resistance | Q37520253 | ||
Pseudomonas aeruginosa: a formidable and ever-present adversary | Q37584596 | ||
Current understanding of fatty acid biosynthesis and the acyl carrier protein | Q37775996 | ||
Recent developments for Pseudomonas vaccines | Q37937369 | ||
Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds. | Q37979307 | ||
Novel therapeutic strategies to counter Pseudomonas aeruginosa infections. | Q37984505 | ||
Design, synthesis, and evaluation of pharmacological properties of cinnamic derivatives as antiatherogenic agents. | Q40338190 | ||
Kinetic, inhibition and structural studies on 3-oxoacyl-ACP reductase from Plasmodium falciparum, a key enzyme in fatty acid biosynthesis | Q42095354 | ||
Macrolactin S, a new antibacterial agent with FabG-inhibitory activity from Bacillus sp. AT28. | Q44616531 | ||
Cofactor-induced conformational rearrangements establish a catalytically competent active site and a proton relay conduit in FabG. | Q44796688 | ||
Evaluation of epigallocatechin gallate and related plant polyphenols as inhibitors of the FabG and FabI reductases of bacterial type II fatty-acid synthase | Q44888115 | ||
Know your chemical space | Q57932475 | ||
P433 | issue | 11 | |
P921 | main subject | Pseudomonas aeruginosa | Q31856 |
allosteric inhibitor | Q70361704 | ||
P304 | page(s) | 2518-2527 | |
P577 | publication date | 2013-09-23 | |
P1433 | published in | ACS Chemical Biology | Q165583 |
P1476 | title | Discovery of an allosteric inhibitor binding site in 3-Oxo-acyl-ACP reductase from Pseudomonas aeruginosa | |
P478 | volume | 8 |
Q35839906 | A Substrate Mimic Allows High-Throughput Assay of the FabA Protein and Consequently the Identification of a Novel Inhibitor of Pseudomonas aeruginosa FabA |
Q55311481 | Advance in Research on Mycobacterium tuberculosis FabG4 and Its Inhibitor. |
Q91594249 | An integrated genomic regulatory network of virulence-related transcriptional factors in Pseudomonas aeruginosa |
Q35299133 | Cloning, expression, purification, crystallization and preliminary X-ray diffraction analysis of AerF from Microcystis aeruginosa, a putative reductase participating in aeruginosin biosynthesis |
Q38706296 | Comparison of two bioinformatics tools used to characterize the microbial diversity and predictive functional attributes of microbial mats from Lake Obersee, Antarctica |
Q30278363 | Dissecting the Structural Elements for the Activation of β-Ketoacyl-(Acyl Carrier Protein) Reductase from Vibrio cholerae |
Q38264138 | Fatty acid biosynthesis revisited: structure elucidation and metabolic engineering |
Q39309646 | Stabilization of Multimeric Proteins via Intersubunit Cyclization. |
Q28550728 | Structural Characterisation of FabG from Yersinia pestis, a Key Component of Bacterial Fatty Acid Synthesis |
Q55316125 | Tachyplesin Causes Membrane Instability That Kills Multidrug-Resistant Bacteria by Inhibiting the 3-Ketoacyl Carrier Protein Reductase FabG. |
Q28080940 | Using modern tools to probe the structure-function relationship of fatty acid synthases |
Q61446735 | Validation of the anti-infective potential of a polyherbal 'Panchvalkal' preparation, and elucidation of the molecular basis underlining its efficacy against Pseudomonas aeruginosa |
Search more.